Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2015: Latest in chronic lymphocytic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.15
Views: 3903
Rating:

Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos

Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) and Dr Jacqueline Barrientos (LIJ Medical Center, New York, USA) discuss the latest in the treatment of chronic lymphocytic leukaemia (CLL).

They consider novel agents and treatment strategies, with a particular focus on new data arising from ASCO 2015.

In particular, they discuss chemo combinations with immunology drugs such as rituximab and the use of single agents such as ibrutinib and idelalisib. They note the possible side effects associated with these new agents but ultimately recognise their positive activity, especially in 17p deletion patients.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation